What Bioventus Shareholders Got Right
Bioventus Inc. 2026 Q3 - Results - Earnings Call Presentation
Bioventus (BVS) Stock Price Slides After Q3 Results Cut Revenue Outlook
Canaccord Genuity Maintains Buy on Bioventus, Lowers Price Target to $18
Bioventus Inc (BVS) Q3 2026 Earnings Call Highlights: Solid Pain and Ultrasonics Growth Offset ...
Bioventus (BVS) Q3 2026 Earnings Call Transcript
Bioventus Inc. (BVS) Q3 2026 Earnings Call Transcript
Bioventus Q3 Earnings Call Highlights
Bioventus (NASDAQ:BVS) Falls After Q3 Revenue Miss and Below-Consensus Sales Guidance Despite EPS Beat
Bioventus: Q3 Earnings Snapshot
Bioventus Reports Third Quarter Financial Results
Bioventus Q3 2026 Earnings Call Transcript
Bioventus Affirms FY2026 Adj EPS Guidance of $0.75-$0.79 vs $0.78 Est; Lowers FY2026 Sales Guidance from $600.000M-$610.000M to $590.000M-$595.000M vs $604.782M Est
Bioventus Q3 Adj. EPS $0.17 Beats $0.16 Estimate, Sales $142.442M Miss $149.461M Estimate
Bioventus to Report Third Quarter of Fiscal Year 2026 Financial Results on November 2, 2026
Canaccord Genuity Maintains Buy on Bioventus, Raises Price Target to $19
Cantor Fitzgerald Reiterates Overweight on Bioventus, Maintains $15 Price Target
Bioventus (BVS) Q2 2026 Earnings Call Transcript
Bioventus (BVS) Stock Still Looks Like A Bargain On Earnings
The Bull Case For Bioventus (BVS) Could Change Following Its Q2 Earnings Surge And Reaffirmed 2026 Guidance
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.